Verastem (VSTM) said late Thursday that the metastatic pancreatic ductal adenocarcinoma patients treated with avutometinib or Avmapki plus defactinib in combination with standard-of-care chemotherapy achieved an overall response rate of 83% as of April 25.
Under the RAMP 205 phase 1/2 trial, the company said 60 patients were treated in one of five dose regimens with the combination of avutometinib and defactinib with gemcitabine and nab-paclitaxel in frontline metastatic PDAC.
The trial showed positive safety and efficacy results, with adverse events remaining generally consistent with the previously announced safety and tolerability profile, the company said.
Verastem said it plans to register a phase 3 front-line metastatic PDAC trial, expected to start in 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。